PARIS (dpa-AFX) - Sanofi (SNYNF, SNY) reported that its fourth-quarter net income attributable to equity holders decreased to 334 million euros from 1.34 billion euros, last year. Earnings per share was 0.26 euros compared to 1.02 euros. Earnings per share excluding the held for exchange Animal Health Business was 0.41 euros compared to 1.03 euros.
Fourth-quarter business net income decreased 6.5% to 1.71 billion euros, and was down 13.5% at CER. Business earnings per share was 1.31 euros, a decrease of 5.8% on a reported basis and 12.9% at CER.
Total Group net sales were 8.72 billion euros, compared to 8.56 billion euros, previous year. Aggregate Group sales were 9.28 billion euros, up 2.3% at 2015 exchange rates. At CER, aggregate Group sales decreased 1.6%. Fourth-quarter sales for Pharmaceuticals decreased 4.7% to 7.28 billion euros, impacted by a decline in Diabetes and Established Rx Products that was partially offset by Genzyme.
In 2015, Aggregate Group sales were 37.06 billion euros, an increase of 9.7% at 2015 exchange rates, and up 2.2% at CER. In 2015, business earnings per share was 5.64 euros, up 8.5% on a reported basis and stable at CER.
Sanofi expects 2016 Business EPS to be broadly stable at CER, barring unforeseen major adverse events.
Copyright RTT News/dpa-AFX